BioSpace News Archive

Glooko, Inc. today announced the appointment of Enrique Conterno to its Board of Directors.

Vedanta Biosciences today announced that management will host investor meetings at the Wells Fargo Virtual Private Biotech Symposium being held on Wednesday, November 1, 2023.

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company) today announced that interim data from the Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for treatment of cystic fibrosis lung disease will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) and that it will host a live webcast to discuss the data in detail and provide a program update on Wednesday, November 1, 2023 at 4:30 p.m. ET.

Aligos Therapeutics, Inc. today announced that an abstract for its capsid assembly modulator – empty (CAM-E) drug candidate, ALG-000184, has been accepted as a late breaking poster at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD).

ViGeneron GmbH announces a peer-reviewed publication in Nature Communications, showcasing the potential of its proprietary dual adeno-associated virus vector technology based on mRNA trans-splicing, REVeRT.

Renibus Therapeutics ® today announced that the first patient has been dosed in the pivotal Phase 3 PROTECT trial of RBT-1, the Company’s first-in-a-new-class preconditioning agent under investigation to reduce post-operative complications following cardiothoracic surgery.

Combined Therapeutics Inc. today announced the participation of Romain Micol, M.D., MPH, Ph.D., President and CEO of Combined Therapeutics, as a speaker at the 11th International mRNA Health Conference, taking place Oct. 31-Nov. 2, 2023, in Berlin, Germany.

Dxcover Limited today announced that it has been awarded first prize for its poster focused on the detection of early-stage tumors across multiple cancers at the European Society for Medical Oncology (ESMO) Congress 2023 in the Innovative Diagnostic Tools category.

Fulgent Genetics, Inc. today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1 to 5, 2023.

XORTX Therapeutics Inc. announces that the special meeting of shareholders that was scheduled for 10:00 a.m. (Calgary time) on October 25, 2023 (the “Meeting”) has been cancelled and will be rescheduled.